Growth inhibition in vitro tests were used to study the susceptibility to pentostam o f different Leishmania strains involved in cutaneous and mucocutaneos leishmaniasis -one glucantime sensitive strain, three naturally glucantime resistant strains and one glucantime resistant line developed by in vitro drug exposure. Contrasting with the high degree , o f glucantime resistance, all strains were sensitive to pentostam. These differences suggest that there is some relationship between chemical structure and in vitro activity fo r these antimonial compounds. These data justify a clinical re-evaluation to compare therapeutic efficacy o f glucantime and pentostam in the treatment o f leishmaniasis.
Antimony-unresponsiveness in visceral and mucocutaneous leishmaniasis are increasing in severity and prevalence worldwide5-6 14 1719. It is not known if antimonial drug insensitivity is attributable to inherent or developed resistance of the parasite, in addition to a variety of host factors that also contribute to chemotherapeutic relapse.
The pentavalent antimony (Sb) complexed to a carbohydrate in the form o f sodium stibogluconate (p en to stam ) o r m eglum ine antim oniate (g lu can tim e) is the only antileishm anial chemotherapeutic agent with clearly favorable therapeutic index. Pentostam, produced in the United Kingdom, is used there, in USA and in most African and Midle-East countries; glucantime, produced in France and in Brazil, is used in french speaking countries and in Latin America. Different dosage schedules have been recommended6 81314, considering the variation o f treatment among the various forms of human leishmaniasis and the importance of the relapse problem. Generally, all antimonial compounds. Growth inhibition.
drug doses are expressed in milligrams of Sb per kilogram per day and the therapeutic schemes are standardized irrespectively of the preparation312. On theoretical basis, it is assumed that both drugs have equivalent therapeutic indexes, i.e., theSbinthetw o formulations are equally removable from the respective carbohydrates. There are no reports of clinical studies com paring th e th erap eu tic effectiveness o f glucantime and pentostam applied in the same dose3 12.
Nevertheless, differences in the susceptibility between both drugs are observed, when glucantime is included in in vitro comparative tests for Sb activity: usually pentostam is more active than glucantime1 11 18. These studies indicate that Leishmania strains may have different susceptibility profiles for each drug, although no rationale for these variations is presented.
A re-evaluation o f this problem is necessary since pentavalent antimonials remain the drugs of choice for leishmaniasis. Here, we report that promastigotes of glucantime resistant Leishmania strains, involved in cutaneous and mucocutaneous leishmaniasis, are sensitive to pentostam, when tested under identical conditions.
MATERIAL AND METHODS
The Glucantime (meglumine antimoniate, 85mg Sb m l'1, batch 020, Rhodia SA, Brazil) and pentostam (sodium stibogluconate, lOOmg Sb m l'1, bacth C54262, WellcomeFoundation Ltd, England) were stored in the dark, at room temperature. Fresh drug samples were used in each experiment. The concentration of these drugs is given as mg of pentavalent antimony according to the manufactures ' information.
The sensitivities of different Leishmania strains to both antimonial drugs, based on promastigotes growth inhibition, were determined as previously described16. Briefly, 25x10s parasites in 5.0ml of fresh medium were incubated with different concen tratio n s o f the drug (pentostam or glucantime). Cultures of each Leishmania strains lacking drug were maintained in parallel as control. The number of parasites was determined by counting in a Coulter Counter (Model D2) and all results were expressed as the mean o f at least two experiments in duplicate. The effect of drug on cell yield was expressed as the percentage of cell number related to control cultures at late log phase.
RESULTS AND DISCUSSION
In previous studies16 we demonstrated that the M9947, M 10995 and LTB259 Leishmania strains are naturally resistant to glucantime: no significative growth effect could be observed in presence of glucantime concentration below 2.0mg Sb/ml -a drug concentration which showed high growth inhibition of sensitive cells. The response of different strains to pentostam and glucantime in the present comparative study is summarized in Table 1 . The data show that these strains are sensitive to pentostam. Even in the case of M 10995 strain, the dose of pentostam which gave rise to about 50 % in growth inhibition was one fourth of that of glucantime used without response. Furthermore, a cell line derived from L. (V.) guyanensis, selected in laboratory for glucantime resistance, showed very little response to 2mg Sb/ml in the form of glucantime, whereas a high growth inhibition was observed in the presence of pentostam, even at lowest concentration tested (0.25mg Sb/ml). These data are simultaneously disturbing and exciting. They may suggest that there is indeed some relation between chemical structure and in vitro activity for these antimonial compounds. Since glucantime and pentostam chemical structures and their biochemical mechanisms of antileishmanial activity are unknown it can be proposed that the two compounds may have different mechanisms of action. On the other hand, the influence of carbohydrate m oiety on antim ony activity demonstrated when the leishmanicidal effects of antimony coupled to yeast mannan were compared to those obtained with glucantime2 may suggest that a differential kinetics of drug accumulation and Sb release could account for the differences observed. U nfortunately, radiolabeled pentostam and glucantime necessary to evaluate the capacity of cells to transport the drugs is commercially unavailable.
Another possibly explanation should consider that Leishmania, as other parasites, has the potential to respond to drug pressure in multiple ways, resulting in drug resistance4. So, the different drug susceptibility profiles observed between pentostam and glucantime may involve different mechanisms of resistance. Drug resistance in Leishmania has been studied with some drugs4 but only few studies have been done with antimonial compounds7 1118 and very little is known about the mechanisms of antimonial resistance.
Although drug sensitivity data obtained with promastigotes in vitro cannot be directly extrapolated to the situation in vitro, these results justify a clinical evaluation in cutaneous and mucocutaneous leishmaniasis, once very seldom pentostam is considered as an alternative after glucantime failure9. 
